Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection

NCT02555293 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

96

Enrollment

OTHER

Sponsor class

Stopped Prematurely terminated due to organisational reasons

Conditions

Malignant Liver Disease
Major Liver Resection

Interventions

DRUG: XIFAXAN® (Rifaximin)

Sponsor

RWTH Aachen University